CASI Pharmaceuticals (CASI Pharmaceuticals) Days Sales Outstanding : 140.76 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is CASI Pharmaceuticals Days Sales Outstanding?

CASI Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2023 was $10.60 Mil. CASI Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $6.87 Mil. Hence, CASI Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 140.76.

The historical rank and industry rank for CASI Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

CASI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.57 Med: 114.24 Max: 365
Current: 124.58

During the past 13 years, CASI Pharmaceuticals's highest Days Sales Outstanding was 365.00. The lowest was 71.57. And the median was 114.24.

CASI's Days Sales Outstanding is ranked worse than
73.9% of 889 companies
in the Biotechnology industry
Industry Median: 71.97 vs CASI: 124.58

CASI Pharmaceuticals's Days Sales Outstanding increased from Dec. 2022 (76.34) to Dec. 2023 (140.76).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

CASI Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for CASI Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Days Sales Outstanding Chart

CASI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

114.24

71.57

87.40

96.43

121.33

CASI Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															76.34	131.63	109.82	124.85	140.76

Competitive Comparison of CASI Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, CASI Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CASI Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Days Sales Outstanding falls into.

CASI Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

CASI Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (12.973	+	9.551)	/	2 )	/	33.879	*	365
=	11.262					/	33.879	*	365
=	121.33

CASI Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (11.656	+	9.551)	/	2 )	/	6.874	*	365 / 4
=	10.6035					/	6.874	*	365 / 4
=	140.76

CASI Pharmaceuticals (NAS:CASI) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

CASI Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals (CASI Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

Executives

James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Wei-wu He	director, 10 percent owner, officer: Chairman and CEO	ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Weihao Xu	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Larry Zhang	officer: President	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Shrotriya Rajesh C Md	director	157 TECHNOLOGY DRIVE, IRVINE CA 92618
Salisbury Franklin Cary Jr	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Wealth Strategy Holding Ltd	10 percent owner	LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK
Alexander A Zukiwski	officer: Chief Medical Officer	200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
George Chi	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Dapeng Li	10 percent owner	BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008
Idg-accel China Growth Fund Iii L.p.	10 percent owner	UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000
Spectrum Pharmaceuticals Inc	10 percent owner	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Sparkle Byte Ltd	10 percent owner	P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000
Ken Ren	director, officer: CEO and Director	3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065